Sigma set for acquisition

Baumgarten, Stefan
June 2007
ICIS Chemical Business;6/25/2007, Vol. 2 Issue 72, p65
Trade Publication
The article reports that Sigma-Aldrich Corp. based in St. Louis, Missouri is planning for further acquisitions. Sigma has been having an annual return on equity at more than 20% and is expected to generate some $350 million in 2007, part of which will go to acquisitions of companies. According to chief executive Jai Nagarkatti, they are expecting to add more acquisitions in 2007 because their core market offered opportunities for growth.


Related Articles

  • in brief.  // Pharmaceutical Technology Europe;Sep2004, Vol. 16 Issue 9, p10 

    This article briefly reports various recent news items from the field of pharmaceutical industry. Recently, Sigma-Aldrich Corp. has announced that it has expanded its fine chemicals capabilities to better serve pharmaceutical manufacturers through its acquisition of another pharmaceutical...

  • Epichem shares bought.  // ICIS Chemical Business;2/19/2007, Vol. 2 Issue 54, p17 

    The article reports on the acquisition of Epichem by Sigma-Aldrich. It will be part of the SAFC Hitech business, which produces high-purity inorganic materials for high-technology applications. Sigma-Aldrich says that the company will help it to achieve growth goals in key markets over the next...

  • Moving into the top ten. O'Driscoll, Cath // European Chemical News;10/31/2005, Vol. 83 Issue 2169, p32 

    This article reports on the advantages of rebranding and acquisition efforts by Sigma-Aldrich as of October 2005. According to Frank Wicks, president of the new business unit, when the company rebranded its fine chemicals division as SAFC in November 2004, it wanted to spell out the message that...

  • Sigma-Aldrich Expands SAFC. Boswell, Clay // Chemical Market Reporter;1/24/2005, Vol. 267 Issue 4, p2 

    Reports that Sigma-Aldrich Corp. has signed an agreement to acquire the Lenexa, Kansas-based JRH Biosciences division of CSL Ltd. for $370 million in cash. Global supplier of cell culture and sera products to the biopharmaceutical industry; Complement to Sigma's SAFC cell culture business;...

  • SWOT Analysis.  // Sigma-Aldrich Corporation SWOT Analysis;Oct2007, p5 

    A business analysis of Sigma-Aldrich Corp., a manufacturer of chemical products for life science and high technology applications, is provided, focusing on its strengths, weaknesses, opportunities for improvement and threats to the company. Strengths include diversified customer base. Weaknesses...

  • SWOT Analysis.  // Sigma-Aldrich Corporation SWOT Analysis;May2008, p5 

    A business analysis of Sigma-Aldrich Corp., a life science and high technology company is provided, focusing on its strengths, weaknesses, opportunities for improvement and threats to the company. Strengths include strong financial performance. Weaknesses include lack of scale. Opportunities for...

  • BREAKING NEWS.  // Pharmaceutical Technology;Jun2007, Vol. 31 Issue 6, p20 

    A calendar of events for the plans of the pharmaceutical companies in the fall of 2007 is presented. The expansion of Amylin Ohio LLC will be held on May 2. The patent infringement action filed by Pall Corp. against Entegris Inc. will be held on May 4. The acquisition of biopharmaceutical...

  • Sigma-Aldrich completes acquisition of BioReliance.  // BioSpectrum;Mar2012, Vol. 10 Issue 3, p73 

    The article reports on the completions of the acquisition of the biopharmaceutical testing services provider BioReliance Holdings Corp. by Sigma-Aldrich Corp. in India.

  • Sigma-Aldrich Sells Its B-Line Systems To Cooper Industries. Papanikolaw, Jim // Chemical Market Reporter;04/03/2000, Vol. 257 Issue 14, p3 

    Reports the acquisition of the B-Line Systems business of Cooper Industries Inc. by Sigma-Aldrich Corp. Value of the deal; Main products of B-Line Systems; 1999 revenue of Cooper Industries.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics